tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksTop Gainers/ Losers/ Active StocksTipRanks Momentum IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Pro Newsletters
Smart Investor
Popular
Smart Growth
New
Research Tools
Trending StocksCompare StocksCompare ETFsMost Visited Websites
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
News
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Notification Center
Top ETFs
Top Smart Score Stocks
Popular
Earnings
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Plans & Pricing
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Top Gainers/ Losers/ Active Stocks
TipRanks Momentum Index
Dividend Stocks
AI Stocks
Largest Companies by Market Cap
ETFs
ETF Center
Top ETFs by Upside
New
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Options
Options Market Overview
Unusual Options Activity
Popular
Most Active Options
Options Volume Leaders
Commodities
Gold
New
Crypto
Crypto Center
Bitcoin
Popular
Ethereum
Currency
Currency Center
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Trending Stocks
Compare Stocks
Compare ETFs
Most Visited Websites
Daily Feeds
Daily Analyst Ratings
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Economic Indicators
Economic Indicators Center
Inflation Rate
Unemployment Rate
Federal Funds Rate
Class Actions
Class Actions
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Dollar Cost Averaging
New
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
News
Portfolio
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Calculators
Compound Interest Calculator
New
Mortgage Calculator
Popular
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
Alzamend Neuro (DE:9ZT0)
FRANKFURT:9ZT0
9ZT0
Alzamend Neuro
Stock Analysis
Analyst Forecasts
News & Insights
Technical Analysis
Chart
Earnings
Dividends
Ownership
Similar Stocks
RESEARCH TOOLS
Top Analyst Stocks
Top Smart Score Stocks
Stock Screener
reports
Holding DE:9ZT0?
Track your performance easily
Link Broker

Alzamend Neuro (9ZT0) Stock News & Sentiment

0 Followers
Alzamend Neuro annouces one-for-fifteen reverse stock split
Premium
The Fly
Alzamend Neuro annouces one-for-fifteen reverse stock split
1y ago
ALZN
Alzamend Neuro submits AL001-MDD01 IN application to FDA
Premium
The Fly
Alzamend Neuro submits AL001-MDD01 IN application to FDA
1y ago
ALZN
Alzamend Neuro receives Study May Proceed letter from FDA for AL001-BD01
Premium
The Fly
Alzamend Neuro receives Study May Proceed letter from FDA for AL001-BD01
1y ago
ALZN
Alzamend Neuro granted extension by Nasdaq panel to regain compliance
Premium
The Fly
Alzamend Neuro granted extension by Nasdaq panel to regain compliance
1y ago
ALZN
Alzamend Neuro submits AL001-BD01 IND application to FDA
Premium
The Fly
Alzamend Neuro submits AL001-BD01 IND application to FDA
1y ago
ALZN
Alzamend Neuro files $25M mixed securities shelf
Premium
The Fly
Alzamend Neuro files $25M mixed securities shelf
1y ago
ALZN
Alzamend Neuro identifies MTD for development of AL001
Premium
The Fly
Alzamend Neuro identifies MTD for development of AL001
2y ago
ALZN
More ALZN News >

9ZT0 News on the Web

Alzamend Neuro Announces Reverse Stock Split
Yahoo Finance
Neutral
Promising Developments in Alzamend Neuro’s Clinical Trials Bolster Buy Rating: A Focused Review on AL001’s Potential in Mental Health Treatment
TipRanks News
Bullish
EXCLUSIVE: Alzamend Neuro Submits IND For Phase IIA Trial Of Next-Gen Lithium Candidate In Major Depressive Disorder
Yahoo Finance
Neutral
Alzamend Neuro Submits IND Application for a Phase IIA Clinical Trial in Major Depressive Disorder Patients of its Next‑Generation Lithium Therapeutic Drug Candidate AL001
Yahoo Finance
Neutral
EXCLUSIVE: Alzamend Neuro To Start Next-Gen Therapy Study For Bipolar Disorder
Yahoo Finance
Neutral
Alzamend Neuro Receives FDA Notification for a Phase IIA Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate, in Bipolar Disorder Patients
Yahoo Finance
Bullish
Alzamend Neuro Granted Extension by Nasdaq Panel to Regain Compliance with the Minimum Bid Price Continued Listing Requirement
Yahoo Finance
Neutral
EXCLUSIVE: Alzamend Seeks FDA Approval For Study For Upgraded Version Of Most Commonly Used Treatment For Bipolar Disorder
Yahoo Finance
Neutral

News Score - Last 7 Days

Neutral
DE:9ZT0
Sector Average
Media Buzz
This Week1 articles
Weekly Average1 articles
News Sentiment
This Week50%
Sector Average64%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is DE:9ZT0’s Media Buzz Sentiment?
1 articles about DE:9ZT0 were published this week. In an average week, 1 articles are published.
    What is DE:9ZT0’s weekly average amount of articles?
    In an average week, 1 articles about DE:9ZT0 are published.
      What is DE:9ZT0’s News Sentiment?
      50% of articles about DE:9ZT0 were positive this week, compared to its sector average of 64%.
        Healthcare Stocks that are Trending in the News
        XFORX4 Pharmaceuticals
        RVTYRevvity
        SRPTSarepta Therapeutics
        NHTCNatural Health Trends
        UTHRUnited Therapeutics
        Showing the stocks with the most bullish news sentiment over the past week

        Become an Expert with TipRanks Premium

        What am I Missing?
        Make informed decisions based on Top Analysts' activity
        Know what industry insiders are buying
        Get actionable alerts from top Wall Street Analysts
        Find out before anyone else which stock is going to shoot up
        Get powerful stock screeners & detailed portfolio analysis
        Subscribe NowSee Plans & Pricing